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Background-—Recent reports indicate that speciﬁc left ventricular (LV) geometric patterns predict recurrent ventricular
arrhythmias in patients with implantable cardioverter-deﬁbrillators and reduced left ventricular ejection fraction (LVEF). However,
this relationship has not been evaluated among patients at risk of sudden cardiac arrest (SCA) in the general population.
Methods and Results-—Adult SCA cases from the Oregon Sudden Unexpected Death Study were compared with geographic
controls with no prior history of SCA. Archived echocardiograms performed closest and prior to the SCA event were reviewed. LV
geometry was deﬁned as normal (normal LV mass index [LVMI] and relative wall thickness [RWT]), concentric remodeling (normal
LVMI and increased RWT), concentric hypertrophy (increased LVMI and RWT), or eccentric hypertrophy (increased LVMI and normal
RWT). Analysis was restricted to those with LVEF ≤40%. A total of 246 subjects were included in the analysis. SCA cases (n=172,
68.613.3 years, 78% male), compared to controls (n=74, 66.812.1 years, 73% male), had lower LVEF (29.47.9% vs
30.86.3%, P=0.021). Fewer cases presented with normal LV geometry (30.2% vs 43.2%, P=0.048) and more with eccentric
hypertrophy (40.7% vs 25.7%, P=0.025). In a multivariate model, eccentric hypertrophy was independently predictive of SCA (OR
2.15, 95% CI 1.08–4.29, P=0.03).
Conclusions-—Eccentric LV hypertrophy was independently associated with increased risk of SCA in subjects with EF ≤40%. These
ﬁndings, now consistent between device-implanted and non-implanted populations, indicate the potential of improving SCA risk
stratiﬁcation from the same noninvasive echocardiogram at no additional cost. ( J Am Heart Assoc. 2016;5:e003715 doi:
10.1161/JAHA.116.003715)
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T he annual incidence of sudden cardiac arrest (SCA) inthe United States is estimated to be over 300 000, with
low survival in the range of 5% to 7%.1,2 The implantable
cardioverter-deﬁbrillator (ICD) has been shown to reduce
mortality rates from SCA in large randomized clinical trials.3,4
Based on the current guidelines, the decision for primary
prevention ICD placement is largely reliant on measurement
of the left ventricular ejection fraction (LVEF).5 However, there
is increasing evidence that LVEF may be inadequate as the
sole SCA risk stratiﬁer, and only a minority of patients
meeting criteria for ICD implantation receive lifesaving
therapies from the device.6 The process of clinical risk
stratiﬁcation clearly requires further improvement.7,8 Further-
more, a recent analysis from the Oregon Sudden Unexpected
Death Study (Oregon SUDS) found that only a small percent-
age of those who do meet these criteria receive ICD
implantation prior to the SCA event.9 This emphasizes the
need for additional parameters to improve SCA risk stratiﬁ-
cation, including those who already meet criteria based on
LVEF, in the general population.
Left ventricular hypertrophy (LVH) and increased left
ventricular (LV) mass are known to be associated with
increased risk of cardiovascular disease, death from cardio-
vascular disease, all-cause mortality, supraventricular and
ventricular arrhythmias, and SCA.10-13 LV mass index (LVMI)
along with relative wall thickness (ratio of wall thickness to LV
diameter) (RWT) have been employed for classiﬁcation of 4 LV
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geometric patterns: normal geometry (normal LVMI and
normal RWT), concentric remodeling (normal LVMI and
increased RWT), eccentric hypertrophy (increased LVMI and
normal RWT), and concentric hypertrophy (increased LVMI
and increased RWT).14 The 4 LV geometry patterns have been
shown to confer unique risks for cardiovascular morbidity and
all-cause mortality, with concentric hypertrophy typically
conferring the highest risk, followed by eccentric hypertrophy,
and then concentric remodeling.15-17 A recent study in
subjects with ICDs and reduced LVEF found the magnitude
of eccentric geometry, as determined by low versus high RWT,
to be a signiﬁcant predictor of recurrent ventricular arrhyth-
mias.18 However, to the best of our knowledge, the risk
associated with the pattern of LV geometry, speciﬁcally
eccentric hypertrophy, has not yet been evaluated in subjects
with reduced LV function at risk of SCA in the general
population. We therefore sought to determine whether
different LV geometry patterns are associated with higher
SCA risk in patients with reduced LVEF.
Methods
Study Population
SCA cases occurring between February 1, 2002 and January
31, 2015 as well as geographic controls were obtained from
subjects in the Oregon Sudden Unexpected Death Study
(Oregon SUDS), a prospective study of out-of-hospital cardiac
arrest in Portland, Oregon (population ~1 million) ongoing
since 2002. Methods for this study have been published in
detail previously.19 Brieﬂy, cases of out-of-hospital cardiac
arrest were identiﬁed through multiple sources including ﬁre
department, ambulance services, local hospital emergency
rooms, and the county medical examiner’s ofﬁce. SCA was
deﬁned as a sudden, unexpected, pulseless condition of likely
cardiac etiology if witnessed, and within 24 hours of last
having been seen in usual state of health if unwitnessed.
Noncardiac causes of death such as trauma, drug overdose,
pulmonary embolism, cerebrovascular accident, or chronic
terminal illness were excluded. Both survivors and nonsur-
vivors of the cardiac arrest event were included in the cases.
A 3-physician review of available medical records/autopsy
reports was performed for adjudication of SCA. Unmatched
geographic controls were used as the comparison group.
Because previous community-based studies have shown ≥80%
of SCA patients to have associated coronary artery disease
(CAD),20 around 80% of controls included in our analysis had
CAD. These subjects were required to have had no history of
prior ventricular arrhythmia or cardiac arrest. CAD was
deﬁned as having ≥50% stenosis of a major coronary artery,
history of myocardial infarction, or history of coronary artery
bypass grafting or percutaneous coronary intervention.
Hypertension was deﬁned as clinical history of hypertension
documented in the medical records. Diabetes mellitus was
deﬁned as documented history of diabetes mellitus in the
medical records or by the use of insulin or other hypoglycemic
agent. Control subjects were ascertained from multiple
sources: chest pain patients attended by emergency medical
services, outpatient clinics, patients undergoing angiography,
and patients from a large health maintenance organization in
the Portland metro area.
All subjects aged ≥18 years with echocardiograms avail-
able and LVEF ≤40% were included in the analysis. Medical
records were reviewed for demographic data and clinical
history (age, sex, race, history of diabetes mellitus, chronic
kidney disease [CKD], obesity [body mass index ≥30 kg/m2],
and hypertension). All archived reports for echocardiograms
performed closest and prior to the SCA event were used for
analysis. This study was approved by the Institutional Review
Boards of Cedars-Sinai Medical Center, Oregon Health and
Science University, and all participating hospitals and health
systems. All survivors of sudden cardiac arrest provided
informed consent; for nonsurvivors this requirement was waived.
Echocardiogram Analysis
LVEF, LV end-diastolic diameter (LVEDD), interventricular
septal thickness at end diastole (IVSd), LV posterior wall
thickness at end diastole (PWd), and presence of valvular
disease were obtained from echocardiograms. From these
values, LV mass was calculated via the linear formula as
recommended by the American Society of Echocardiography,
0.8 9 {1.04([LVEDD+PWd+IVSd]3[LVEDD]3)}+0.6 g,14 and
LVMI was calculated by dividing the LV mass by the body
surface area (g/m2). RWT was calculated by multiplying 2
times PWd divided by LVEDD. A cutoff of 134 g/m2 for males
and 110 g/m2 for females was used to deﬁne an increased
LVMI.21 RWT was deﬁned as increased if ≥0.45.15 Classiﬁca-
tion of LV geometry, based on LVMI and RWT, was into normal
(normal LVMI and normal RWT), concentric remodeling (normal
LVMI and increased RWT), concentric hypertrophy (increased
LVMI and RWT), and eccentric hypertrophy (increased LVMI
and normal RWT).14 Subjects with severe aortic stenosis,
hypertrophic cardiomyopathy, and LVEF >40% were excluded.
Statistical Analysis
Cases and controls were compared using independent-
samples t-tests and chi-squared tests for continuous and
categorical variables, respectively. The different LV geometry
types in SCA cases were compared using ANOVA and chi-
squared test for continuous and categorical variables,
respectively. Equality of variances was tested using the
Levene test, and for those parameters that did not have equal
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variances the nonparametric Kruskal-Wallis test was used
instead of ANOVA. A 2-tailed P value of ≤0.05 was considered
statistically signiﬁcant. Multivariable logistic regression was
used to determine the odds ratio (OR) for independent
association between LV geometry and SCA, using normal LV
geometry as the reference. Independent models were devel-
oped that adjusted for demographic parameters. To determine
the independent effect of RWT on SCA risk, we performed a
similar analysis for RWT as a continuous variable and a
categorical variable using the lowest quartile as the cutoff
(<0.31). All analyses were performed using IBM SPSS
Statistics for Windows, version 21.0 (IBM Corp, Armonk, NY).
Results
Demographic and Clinical Characteristics
Echocardiographic data on LV geometry were available from
535 cases and 414 controls. After exclusion of subjects with
preserved LVEF >40%, a total of 246 subjects (172 cases, 74
controls) were included in the analysis (Table 1). Cases were
more likely than controls to have hypertension (77.9% versus
64.9%, P=0.03) and CKD (44.2% versus 20.3%, P<0.001).
There were no signiﬁcant differences in other demographic
and medical history parameters evaluated.
Characteristics of SCA Cases With Different LV
Geometry
We compared several parameters across LV geometry types
in SCA cases (Table 2). History of prior myocardial infarction
was highest in concentric hypertrophy. Otherwise, there were
no signiﬁcant differences in demographics or medical history.
LVMI and LVEDD were highest and LVEF lowest in eccentric
hypertrophy. IVSd and PWd were highest in concentric
hypertrophy. RWT was lowest in normal and eccentric
hypertrophy. A similar comparison was made in the
unmatched geographic controls (Table S1). Findings were
similar, except hypertension prevalence was highest in
concentric hypertrophy, and there were no signiﬁcant differ-
ences in history of myocardial infarction or LVEF between
groups.
Echocardiographic Characteristics of Cases and
Controls
With regard to echocardiographic parameters (Table 3), cases
were signiﬁcantly more likely than controls to have a higher
mean LVMI (142.443.3 vs 123.238.2 g/m2, P<0.001),
increased LVMI (>134 g/m2 for males, >110 g/m2 for
females) (55.8% vs 39.2%, P=0.017), higher mean LVEDD
(60.19.5 vs 56.79.0 mm, P=0.003), and lower mean LVEF
(29.47.9% vs 30.86.3%, P=0.021). There were no signif-
icant differences in IVSd, PWd, or RWT between groups.
Risk of SCA Associated With Abnormal LV
Geometry
The LV geometry pattern differed signiﬁcantly in SCA cases
compared to controls. Normal LV geometry was signiﬁcantly
less prevalent (30.2% vs 43.2%, P=0.048), and eccentric
hypertrophy was more prevalent (40.7% vs 25.7%, P=0.025)
(Figure), in cases compared to controls. There were no
signiﬁcant differences in occurrence of concentric remodeling
and concentric hypertrophy between groups.
In multivariable analysis adjusting for age, sex, and race
(Table 4), eccentric hypertrophy was independently predictive
of SCA, increasing the odds by over 2-fold compared to
normal LV geometry (OR 2.15, 95% CI 1.08-4.29, P=0.03).
Concentric remodeling and concentric hypertrophy were not
statistically signiﬁcant predictors of SCA. When RWT was
examined as an independent predictor of SCA, both as a
continuous variable and employing a cutoff of <0.31 (lowest
quartile in our sample), RWT was not associated with SCA.
Discussion
To the best of our knowledge, there are no existing
community-based data on the risk of SCA associated with
different LV geometry patterns in patients with reduced LVEF.
This is likely to be the ﬁrst study to report that eccentric
hypertrophy is predictive of SCA in subjects with reduced LV
function in the general population. The other LV geometry
Table 1. Baseline Demographic and Clinical Characteristics
of SCA Cases Versus Controls With EF ≤40%
Total (n=246) Case (n=172) Control (n=74) P Value
Age, y 68.613.3 66.812.1 0.32
Male sex 134 (77.9%) 54 (73.0%) 0.40
Race* 0.34
White 141 (82.5%) 62 (87.3%)
Black 23 (13.5%) 5 (7.0%)
Other 7 (4.1%) 4 (5.6%)
Hypertension 134 (77.9%) 48 (64.9%) 0.03
Diabetes mellitus 84 (48.8%) 32 (46.0%) 0.68
CKD 76 (44.2%) 15 (20.3%) <0.001
Obesity (BMI ≥30 kg/m2) 67 (39.0%) 32 (43.2%) 0.53
CKD indicates chronic kidney disease; EF, ejection fraction; SCA, sudden cardiac arrest.
Data are presented as meanSD or n (%). BMI indicates body mass index.
*Race data available for 171 cases and 71 controls.
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patterns, concentric remodeling and concentric hypertrophy,
were not found to be signiﬁcantly associated with SCA. These
ﬁndings indicate that LV eccentric hypertrophy confers
increased risk of SCA independent of reduced LVEF, and
both can be measured from the same noninvasive echocar-
diogram, potentially providing enhanced clinical utility at no
additional cost. Following on the recently published similar
ﬁndings in a primary prevention device population, the
Multicenter Automatic Deﬁbrillator Implantation Trial with
Cardiac Resynchronization Therapy (MADIT-CRT),18 these data
from nonimplanted patients who suffered SCA indicate the
signiﬁcant potential of this marker to improve clinical risk
stratiﬁcation.
Abnormal LV geometry has also been studied in the
context of overall cardiovascular morbidity and mortality and
shown to be associated with worse prognosis and outcomes.
Analysis from 3216 subjects in the Framingham Heart Study
found that event rates of cardiovascular disease or death
were highest in concentric hypertrophy, followed by eccentric
hypertrophy, then concentric remodeling, and normal geom-
etry.16 Another analysis from 5098 subjects in the Multi-
Ethnic-Study of Atherosclerosis (MESA) showed LV geometry
based on cardiac MRI was a better predictor of stroke and
coronary heart disease compared to LV mass alone.22 Similar
associations were reported in several other disease popula-
tions, such as those with CAD,17 post–myocardial infarc-
tion,23 atrial ﬁbrillation,24 hypertension,15,25-28 CKD,27
preserved LV function,28-30 and advanced age.31 However,
most recently an analysis among patients with LVEF ≤30%
enrolled in the MADIT-CRT study found the magnitude of
eccentric remodeling to be predictive of risk of recurrent
ventricular arrhythmias.18 Now, our ﬁndings provide additional
insight into the relationship between LV geometry and SCA
among subjects with reduced LV function in the general
population.
Among the SCA cases in our study, 30% had normal
geometry, and 41% had eccentric hypertrophy on echocar-
diograms prior to the event. In contrast, controls had
signiﬁcantly more subjects with normal geometry (43%) and
fewer with eccentric hypertrophy (26%). There were no
signiﬁcant differences in concentric remodeling and hyper-
trophy prevalence compared between groups. On comparison
between LV geometry patterns, the eccentric hypertrophy
subgroup was observed to have the lowest value of LVEF.
Table 2. Characteristics by LV Geometry in SCA Cases With EF ≤40%
Total (n=172) Normal (n=52)
Concentric
Remodeling (n=24)
Concentric
Hypertrophy (n=26)
Eccentric
Hypertrophy (n=70) P Value
Age, y 65.012.1 72.010.6 72.514.0 68.614.2 0.056
Male sex 42 (80.8%) 19 (79.2%) 18 (69.2%) 55 (78.6%) 0.700
Race* 0.201
White 42 (80.8%) 23 (100%) 21 (80.8%) 55 (78.6%)
Black 8 (15.4%) 0 (0%) 8 (15.4%) 10 (14.3%)
Other 2 (3.9%) 0 (0%) 0 (0%) 5 (7.1%)
CAD 40 (76.9%) 19 (79.2%) 23 (88.5%) 52 (74.3%) 0.519
Hypertension 40 (76.9%) 19 (79.2%) 19 (73.1%) 56 (80.0%) 0.901
Diabetes mellitus 24 (46.2%) 15 (62.5%) 15 (57.7%) 30 (42.9%) 0.289
CKD 17 (32.7%) 11 (45.8%) 15 (57.7%) 33 (47.1%) 0.173
Obesity (BMI ≥30 kg/m2) 20 (38.5%) 11 (45.8%) 14 (53.9%) 22 (31.4%) 0.206
History of MI 35 (67.3%) 15 (62.5%) 22 (84.6%) 38 (54.3%) 0.048
Echocardiographic parameters
LV mass index, g/m2 104.016.6 107.721.2 167.236.7 173.732.5 <0.001
LVEDD, mm 58.27.1 48.96.7 55.75.7 67.17.5 <0.001
LVEF, % 29.97.7 32.46.4 31.56.4 27.18.6 0.010
IVSd, mm 9.41.6 11.81.7 13.82.8 11.72.6 <0.001
PWd, mm 9.21.4 11.61.1 13.71.4 10.71.6 <0.001
RWT 0.320.06 0.480.07 0.500.08 0.320.06 <0.001
Data are presented as meanSD or n (%). BMI indicates body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; EF, ejection fraction; IVSd, interventricular septum in
diastole; LV, left ventricular; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; MI, myocardial infarction; PWd,
posterior wall in diastole; RWT, relative wall thickness (calculated as: [29PWd]/LVEDD); SCA, sudden cardiac arrest.
*Race data available for 52 normal, 23 concentric remodeling, 26 concentric hypertrophy, 70 eccentric hypertrophy.
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Eccentric hypertrophy was found to increase risk of SCA by
over 2-fold, even when adjusted for demographic parameters.
These ﬁndings suggest that abnormal LV geometry, speciﬁ-
cally eccentric hypertrophy, increases risk for SCA, which may
aid in further SCA risk stratiﬁcation in subjects with reduced
LV function in the general population.
A potential explanation for eccentric hypertrophy increas-
ing risk for SCA compared to the other LV geometry patterns
may be related to the increased arrhythmogenic risk associ-
ated speciﬁcally with eccentric hypertrophy.32 This has been
supported in the literature by a recent study from Draper et al
that looked at ventricular tachycardia or ﬁbrillation (VT/VF)
occurrence in subjects with reduced LV function in the
general population.33 They found among the 127 patients
studied, occurrence of ventricular arrhythmias was highest in
those with eccentric hypertrophy, compared to concentric
remodeling/hypertrophy and normal geometry. The MADIT-
CRT study found decreased RWT in patients with eccentric
hypertrophy to be associated with higher risk of ventricular
arrhythmias compared to those with higher RWT.18 Enlarge-
ment in LV size could potentially be the driving force behind
increased arrhythmogenesis in eccentric hypertrophy as well
as decreased RWT. LV diameter has been shown to be
independently predictive of SCA and to have an additive effect
with LVEF on predicting SCA risk.34,35 Two studies, 1 in
patients post–myocardial infarction36 and the other in
patients with severe LV dysfunction,37 found that increased
LV size was predictive of ventricular arrhythmias and frequent
premature ventricular contractions (PVC). This association
was further supported in a study that found reduction of LV
end-systolic size in patients undergoing cardiac resynchro-
nization therapy reduced occurrence of PVCs and VT/VF
events.38 With eccentric hypertrophy commonly occurring
secondary to an increase in preload volume and resulting in
enlargement of the LV, the increased ventricular arrhythmic
Table 3. Comparison of Echocardiographic Characteristics of
SCA Cases and Controls With EF ≤40%
Case (n=172) Control (n=74) P Value
LV mass index, g/m2 142.443.3 123.238.2 <0.001
Increased LV mass index 96 (55.8%) 29 (39.2%) 0.017
LVEDD, mm 60.19.5 56.79.0 0.003
LVEF, % 29.47.9 30.86.3 0.021
IVSd, mm 11.32.6 10.92.7 0.143
PWd, mm 10.82.1 10.32.3 0.061
RWT 0.370.10 0.370.10 0.883
RWT ≥0.45 50 (29.1%) 23 (31.1%) 0.752
LV geometry
Normal 52 (30.2%) 32 (43.2%) 0.048
Concentric remodeling 24 (14.0%) 13 (17.6%) 0.467
Concentric hypertrophy 26 (15.1%) 10 (13.5%) 0.744
Eccentric hypertrophy 70 (40.7%) 19 (25.7%) 0.025
Data are presented as meanSD or n (%). EF indicates ejection fraction; IVSd,
interventricular septum in diastole; LV, left ventricular; LVEDD, left ventricular end-
diastolic diameter; LVEF, left ventricular ejection fraction; LVH, left ventricular
hypertrophy; PWd, posterior wall in diastole; RWT, relative wall thickness; SCA, sudden
cardiac arrest.
Figure. Distribution of LV geometry patterns in sudden cardiac
arrest case versus control subjects. Cases were signiﬁcantly more
likely to have eccentric LV hypertrophy. P values were obtained
using chi-squared test for each LV geometry type, with a value of
≤0.05 indicating a statistically signiﬁcant difference.
Table 4. Odds Ratios of SCA Associated With Eccentric
Hypertrophy
OR 95% CI P Value
Unadjusted (n=246)
Normal 1 1 —
Concentric remodeling 1.14 0.51 to 2.54 0.756
Concentric hypertrophy 1.60 0.68 to 3.75 0.280
Eccentric hypertrophy 2.27 1.16 to 4.44 0.017
Model 1 (n=246)
Normal 1 1 —
Concentric remodeling 1.06 0.47 to 2.39 0.890
Concentric hypertrophy 1.62 0.68 to 3.84 0.278
Eccentric hypertrophy 2.26 1.15 to 4.45 0.018
Model 2 (n=242)
Normal 1 1 —
Concentric remodeling 0.98 0.43 to 2.25 0.958
Concentric hypertrophy 1.56 0.63 to 3.86 0.337
Eccentric hypertrophy 2.15 1.08 to 4.29 0.030
Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, and race. CI indicates
conﬁdence interval; OR, odds ratio; SCA, sudden cardiac arrest.
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risk associated with this LV geometric pattern is a potential
explanation linking the association we found between eccen-
tric hypertrophy and SCA.
It is possible that adverse myocardial interstitial remodel-
ing could have a role in increasing arrhythmic risk in eccentric
hypertrophy. Increased interstitial collagen has been found in
diseased hearts, such as in noninfarcted tissue in myocardial
infarction or hypertensive hypertrophy.39 Presence of ﬁbrosis
can create conditions that promote reentry and ventricular
arrhythmogenesis. This has been supported in a study looking
at patients with nonischemic dilated cardiomyopathy that
found presence of ﬁbrosis on cardiac magnetic resonance
increases risk of SCA, ICD shocks, nonfatal VF, and sustained
VT.40 However, concentric hypertrophy and eccentric hyper-
trophy have different collagen remodeling patterns.41 These
different remodeling patterns may carry unique arrhythmic
risks. Abnormal myocardial ﬁbrosis, common to all forms of
LVH, is the leading substrate for ventricular arrhythmogene-
sis. However, due to ventricular wall thinning and dilatation,
increased wall stress may further increase arrhythmic risk in
patients with eccentric hypertrophy, even at a relatively late
stage of LV remodeling. Further studies would be needed to
explore this hypothesis.
Limitations
Given the relatively infrequent occurrence of SCA compared
to the size of the general population, a case-control design
was employed that has some inherent limitations. Analysis
was restricted to subjects with appropriate echocardiograms
available, and since SCA may occur as the ﬁrst presentation
or evidence for CAD, sampling of subjects may be biased.
Furthermore, echocardiograms used in this study were
obtained based on routine clinical practice, and thus,
reproducibility of the measurements could not be assessed.
Also, as expected, the control subjects had lower rates of
echocardiography as well as a lower proportion of severe LV
systolic dysfunction. Multivariable models were developed;
however, for any observational study, unknown confounders
cannot be excluded with certainty. The strength of this study
is the community-based prospective ascertainment of SCA
cases for sampling of this adverse event in the general
population.
Conclusion
Eccentric hypertrophy is independently predictive of SCA in
subjects with EF ≤40% in the general population. Given the
well-recognized limitations of using LVEF as the sole risk
stratiﬁer and the recent similar observations made from the
MADIT-CRT population, our ﬁndings suggest that evaluation of
LV geometry may supplement and enhance LVEF-based SCA
risk stratiﬁcation.
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Table S1. Characteristics by LV geometry in controls with EF ≤40% 
Total (n=74) Normal (n= 
32) 
Concentric 
Remodeling 
(n= 13) 
Concentric 
Hypertrophy 
(n= 10) 
Eccentric 
Hypertrophy 
(n= 19) 
P Value 
Age (years) 68.3±9.4 67.1±13.1 66.0±13.2 64.6±15.3 0.764 
Male Sex 24 (75.0%) 12 (92.3%) 5 (50.0%) 13 (68.4%) 0.144 
Race*     0.473 
Caucasian 28 (93.3%) 11 (84.6%) 7 (77.8%) 16 (84.2%)  
African American 1 (3.3%) 1 (7.7%) 2 (22.2%) 1 (5.3%)  
Other 1 (3.3%) 1 (7.7%) 0 (0.0%) 2 (10.5%)  
Coronary Artery 
Disease 
24 (75%) 10 (76.9%) 6 (60.0%) 18 (94.7%) 0.156 
Hypertension 19 (59.4%) 6 (46.2%) 10 (100%) 13 (68.4%) 0.047 
Diabetes 14 (43.8%) 5 (38.5%) 6 (60.0%) 9 (47.4%) 0.761 
Chronic Kidney 
Disease 
7 (21.9%) 5 (38.5%) 0 (0.0%) 3 (15.8%) 0.139 
Obesity (BMI ≥30 
kg/m2) 
13 (40.6%) 7 (53.9%) 60 (60.0%) 6 (31.6%) 0.410 
History of MI 20 (62.5%) 7 (53.9%) 6 (60.0%) 14 (73.7%) 0.696 
Echocardiographic 
parameters 
     
LV Mass Index (g/m2) 99.5±18.3 99.3±17.2 157.3±25.2 161.6±34.8 <0.001 
LVEDD (mm) 57.0±9.4 47.9±4.9 55.0±4.6 63.2±6.8 <0.001 
LVEF (%) 31.6±7.2 30.8±4.9 31.7±5.2 29.2±5.9 0.581 
IVSd (mm) 9.5±1.8 11.3±1.9 13.5±2.1 11.6±3.5 <0.001 
PWd (mm) 8.6±1.6 11.7±1.2 13.5±1.6 10.7±1.4 <0.001 
RWT 0.31±0.08 0.49±0.06 0.49±0.08 0.34±0.04 <0.001 
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Data are presented as mean ± SD or n (%). BMI-body mass index; LV-left ventricular; LVEDD-left 
ventricular end-diastolic diameter; LVEF- left ventricular ejection fraction; MI-myocardial infarction; 
IVSd-interventricular septum in diastole; PWd-posterior wall in diastole; RWT-relative wall thickness 
(calculated as: [2 x PWd]/LVEDD); LVH-left ventricular hypertrophy 
*Race data available for 30 normal, 13 concentric remodeling, 9 concentric hypertrophy, 19 eccentric 
hypertrophy 
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